Urinary renin and angiotensinogen in type 2 diabetes: Added value beyond urinary albumin?

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1646-1652

  Persson, Frederik ^a   Lu, Xifeng ^b   Rossing, Peter ^c,d   Garrelds, Ingrid M ^b   Danser, A H Jan ^b   Parving, Hans Henrik ^c,e  

^a STENO DIABETES CENTER   (Denmark)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c AARHUS UNIVERSITY   (Denmark)

^d NNF Center for Basic Metabolic Research   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

albuminuria; angiotensinogen; renin angiotensin aldosterone system; rennin; rennin inhibition; type 2 diabetes

Indexed keywords

ALBUMIN; ALISKIREN; ANGIOTENSINOGEN; HEMOGLOBIN A1C; IRBESARTAN; PLACEBO; PRORENIN; RENIN;

ALBUMIN URINE LEVEL; ALBUMINURIA; ANGIOTENSINOGEN URINE LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNORADIOMETRIC ASSAY; KIDNEY PARENCHYMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN URINE LEVEL; URINALYSIS; URINARY EXCRETION; URINE LEVEL;

EID: 84880573170     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328362217c     Document Type: Article

References (29)

1. Nakano D, Kobori H, Burford JL, Gevorgyan H, Seidel S, Hitomi H, et al. Multiphoton imaging of the glomerular permeability of angiotensinogen. J Am Soc Nephrol 2012; 23:1847-1856.
2. Pohl M, Kaminski H, Castrop H, Bader M, Himmerkus N, Bleich M, et al. Intrarenal renin angiotensin system revisited: role of megalindependent endocytosis along the proximal nephron. J Biol Chem 2010; 285:41935-41946.
3. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007; 18:1558-1565.
4. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal reninangiotensin system status in hypertensive patients. Hypertension 2009; 53:344-350.
5. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol 2012; 23:1181-1189.
6. Kang JJ, Toma I, Sipos A, Meer EJ, Vargas SL, Peti-Peterdi J. The collecting duct is the major source of prorenin in diabetes. Hypertension 2008; 51:1597-1604.
7. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL, et al. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 2004; 44:223-229.
8. Leyssac PP. A micropuncture study of glomerular filtration and tubular reabsorption of endogenous renin in the rat. Renal Physiol 1978; 1:181-188.
9. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens 2011; 29:2147-2155.
10. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CDA, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32:1873-1879.
11. Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E, Danser AHJ. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J Hypertens 2011; 29:2454-2461.
12. Price DA, Porter LE, Gordon M, Fisher NDL, DeOliveira JM, Laffel LMB, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10:2382-2391.
13. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998; 16:853-862.
14. Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30:271-274.
15. Batenburg WW, de Bruin RJA, van Gool JMG, Muller DN, Bader M, Nguyen G, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Art Thromb Vasc Biol 2008; 28:1151-1157.
16. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997; 29:1240-1251.
17. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52:1076-1083.
18. Krop M, van Veghel R, Garrelds IM, de Bruin RJA, van Gool JM, van den Meiracker AH, et al. Cardiac renin levels are not influenced by the amount of resident mast cells. Hypertension 2009; 54:315-321.
19. Danser AHJ, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM, Saxena PR, et al. Prorenin, renin, angiotensinogen, and angiotensinconverting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997; 96:220-226.
20. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:E1-E8.
21. Fisher NDL, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
22. Sawaguchi M, Araki SI, Kobori H, Urushihara M, Haneda M, Koya D, et al. Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. J Diabetes Investig 2012; 3:318-324.
23. Mills KT, Kobori H, Hamm LL, Alper AB, Khan IE, Rahman M, et al. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant 2012; 27:3176-3181.
24. Hirsch AT, Opsahl JA, Lunzer MM, Katz SA. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction. Am J Physiol 1999; 276:H1818-H1826.
25. van Kats JP, Danser AHJ, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MADH. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98:73-81.
26. Alge J, Karakala N, Neely B, Janech M, Tumlin J, Chawla L, et al. Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol 2012; 8:184-193.
27. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de ZD, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
28. Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J Hypertens 2010; 28:1983-1994.
29. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374:543-550.